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Undifferentiated embryonal sarcoma of the liver (UESL) represents a heterogeneous group of tumors derived from
mesenchymal tissues. Earlier cytogenetic studies in limited cases demonstrated that UESL is associated with a
recurrent translocation t(11;19)(q11;q13.3-q13.4) or add(19)(q13.4). In this report, we present our array comparative
genomic hybridization (aCGH), fluorescence in situ hybridization (FISH) findings, and a missense mutation of TP53
gene by DNA sequencing in a 19-year-old patient with UESL. The data were compared to laboratory findings
reported by previous studies.
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mutationBackground
Undifferentiated embryonal sarcoma of the liver (UESL)
is very rare and highly malignant. It occurs predomin-
antly in children with a peak incidence in the age range
of 6–10 years without sexual predomination [1]. Modern
supportive therapy and multimodal treatment, including
tumor resection and adjuvant chemotherapy, have
improved survival [2]. UESL is sometimes misdiagnosed
as other types of sarcomas involving the liver [3], includ-
ing as a poorly differentiated or sarcomatoid variant of
hepatocellular carcinoma [4] or as benign hepatic lesions
[5]. Currently, oncogenesis of UESL remains uncertain.
Multiple cytogenetic studies of sporadic cases demon-
strated that UESL frequently harbors chromosomal
rearrangements of 19q13.4, including the translocation
t(11;19)(q11;q13.3/13.4) [6] and add(19)(q13.4) [7]. Sowery
et al. used a conventional CGH technique to investigate
chromosomal imbalances in six patients with UESL and
reported losses or gains of whole chromosomes or partial
chromosomal regions [8]. Using DNA sequencing analysis,
the breakpoint of the translocation t(11;19) on 11q was* Correspondence: junqiniu@yahoo.com.cn
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reproduction in any medium, provided the ordetected in the MALAT1 gene, i.e., the MALAT1 gene was
rearranged at t(11;19) [9]. Point mutations of the TP53
gene were also detected in three UESL cases [10,11]. To
our knowledge, we are the first to use high-resolution
array-CGH analysis (aCGH) to detect more subtle seg-
mental genomic imbalances, which were followed by
fluorescence in situ hybridization (FISH) to confirm some
of the selected anomalies identified by aCGH. In addition,
given that a hemizygous deletion of the TP53 gene was
identified in our case by aCGH and FISH, subsequent
DNA sequencing was performed to identify additional
gene mutations in the rest of the TP53 allele in this case.Case presentation
A 19-year-old girl was admitted to the Surgical Department
of the First Hospital of Jilin University because of continu-
ous abdominal distension and increasing abdominal girth.
An abdominal ultrasound revealed the presence of a lesion
in the right lobe of the liver (approx. 19×17 cm). Com-
puted tomography revealed a well-defined, low-density
mass in the right lobe. The initial impression by the CT
scan was possible hepatic echinococcosis. Laboratory inves-
tigations showed a normal serum α-fetoprotein level,
normal albumin, normal aspartate aminotransferase (AST),
and normal alanine aminotransferase (ALT). Due to theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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close contact with pets, the primary diagnosis was hepatic
echinococcosis. An open biopsy of the liver mass was per-
formed, and subsequently, the patient underwent right
hemihepatectomy.
The gross specimen weighed 3200 g and measured
25× 19× 12 cm. The lesion was well demarcated from the
surrounding hepatic parenchyma by a fibrous pseudocap-
sule. The tumor had multiple greyish-white, partially mu-
coid, fluid-filled cysts together with areas of hemorrhage
and necrosis (Figure 1A). On microscopic examination,
there was no hydatid or hydatid scolex in the fluid. The
tumor was composed of a pleomorphic lesion with an
abundance of abnormal cells, including multinucleated
cells, primitive undifferentiated mesenchymal cells, and
fusiform cells (Figure 1B). Immunohistochemically, the
tumor expressed vimentin and macrophage-myeloid asso-
ciated antigen (CD68) but did not express actin, epithelial
membrane antigen (EMA), smooth-muscle actin (SMA),
or α-fetoprotein. The pathological diagnosis was undiffer-
entiated embryonal sarcoma of the liver with resection
margins free of disease. Magnetic resonance imaging
(MRI) demonstrated no evidence of disease one month




Genomic DNA was extracted from the patient’s paraffin-
embedded tumor tissue block using the QIAamp DNA
FFPE tissue kit (QIAGEN, Hilden, Germany) according to
the manufacturer’s protocols. Human genomic reference
DNA was purchased from Promega (Promega Corpor-
ation, Madison, WI, USA). The sonicated patient DNA
and reference DNA were labeled with either cyanine 3
(Cy-3) or cyanine 5 (Cy-5) by random priming (Trilink
Biotechnologies, San Diego, CA, USA). These samples
were subsequently hybridized to a NimbleGen high-
capacity 385 K oligo microarray chip (Roche/NimbleGen
System Inc., Madison, WI, USA) by incubating in a MAUIA
2cm 2
Figure 1 Tumor morphology. (A) Resected specimen. (B) Pleomorphic le
and others with eosinophilic inclusions in the cytoplasm on the left upper
corner.Hybridization System (BioMicro Systems, Salt Lake City,
UT, USA) for 18 h according to NimbleGen’s CGH proto-
cols. The array was scanned at 532 and 635 nm using the
GenePix scanner (Molecular Devices, Sunnyvale, CA,
USA). NimbleScan and SignalMap (NimbleGen System
Inc, Madison, WI, USA) were applied for data analysis.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on paraffin slides cut from
the paraffin-embedded tumor tissue using multiple DNA
probes, including the locus-specific probes LSI D5S21/
EGR1, LSI c-MYC, LSI IGH/FGFR3 and LSI TP53. All
the probes were purchased from a commercial source
(Abbott Molecular Inc., Des Plaines, IL, USA) and were
used according to the manufacturer’s protocols with
minor modifications.
DNA sequencing analysis of the TP53 gene mutation
Polymerase chain reaction (PCR) was performed using
primers designed to target exons 2–11 of the genomic
DNA of the TP53 gene (GenBank accession number
NM_000546.4). Mutation nomenclature follows the num-
bering recommended by the Human Genome Variation
Society with +1 nucleotide as the A of the ATG initiation
codon [12]. The 25 μl PCR mixture contained 50 ng of
template DNA, 1X PCR buffer, 0.2 mmol/L dNTP mix,
50 ng of each primer, 2.5 mmol/L MgCl2 and 1 unit of
AmpliTaq Gold (Applied Biosystems, Foster City, CA,
USA). The ddNTP terminator reaction was carried out
with ABI BigDye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems). The data were collected on an ABI
3130xl Genetic Analyzer (Applied Biosystems). Mutation
Surveyor (SoftGenetics, State College, PA, USA) was the
primary tool used in the data analysis.
Results
The losses and gains of chromosomal material as well as
their specific genomic sizes, as detected by aCGH, are
presented in Table 1. The tumor had losses of multiple
chromosomal regions, including 1p13.1, several regionsB
00X
sion with an abundance of bizarre cells, including multinucleated cells
corner; primitive undifferentiated fusiform cells on the right lower




(NCBI Build 36.3) (bp)
Size (Mb) Number of genes
(Interesting genes)Loss Gain
1pter-p36.33 712558-2243993 1.53 73 (NOC2L, TNFRSF18, TNFRSF4)
1p13.1 116168951-117581500 1.4 21 (CD9P1, TRIM45)
2pter-p25.3 6477-3368813 3.4 19 (TSSC1)
2q11.2-q13 100018907-112693871 12.7 129
2q14.1 114650166-115262744 0.6 1 (intron of DPP10)
2q14.1 115268926-115418974 0.15 1 (intron of DPP10)
2q14.1-q21.3 115425158-136187596 20.8 166
2q22.1-q23.3 137775162-153625228 15.9 61
2q23.3-q24.1 153631373-159375017 5.7 27
2q24.1-q24.3 159381356-165156442 5.8 42
2q24.3 165162652-165968804 0.78 6
2q24.3 167625090-169268884 1.6 9 (STK39)
3pter-p12.1 37570-85662543 85.6 718
4pter-p15.2 191-26362651 26.4 255 (FGFR3)
4p13 42031490-43193968 1.2 4
4p13-p11 43200181-49200003 6.0 37
4p11-qter 49275218-191262539 142 931
4q31.1 141506279-141625040 0.12 2 (SCOC, CLGN)
5pter-p15.31 68753-6212561 6.2 49 (AHRR, TRIP13, TERT, NDUFS6, ADAMTS16)
5q21.2 102968812-104225203 1.3 0
5q21.3 105381409-105843899 0.47 0
5q21.3-q22.1 107493790-110062750 2.6 11
5q23.1 118512522-121281380 2.8 12
5q23.2-q23.3 124356361-129125131 4.8 26
5q31.1-q31.2 133375174-136043822 2.7 36 (TCF7)
5q31.2 136231375-136300191 0.07 0
5q31.2-q32 136925251-144481375 7.6 158 (WNT8A, EGR1)
5q32-q33.1 145268956-148600233 3.3 31
5q33.2-q33.3 155168994-156318797 1.5 3 (SGCD)
5q34 166500163-166900243 0.4 1 (ODZ2)
5q35.2-qter 176325212-180650172 4.3 129 (FGFR4, SCGB3A1, FLT4)
6q22.33 129843975-130381431 0.54 4
8q24.12-qter 121625189-146262725 24.62 210 (HAS2, MYC)
9p24.1 8412749-8731371 0.318 2 (PTPRD)
9q34.11 129650050-130125185 0.475 20 (NAIF1, CIZ1)
9q34.3 140012561-140225027 0.213 3 (CACNA1B)
10pter-q22.1 87523-71568878 71.6 585
11pter-p15.4 187565-7193965 7.0 298
14q12-qter 25075026-106356252 81.3 1049 (IGH)
15q11.2-qter 20262522-100281493 80 1084
16pter-p13.3 53-5456277 5.5 267
17pter-p12 18890-15187519 15.2 334 (TP53)
19p13.3-p13.11 2250072-19137619 19.1 586
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Table 1 Summary of genomic imbalances detected by aCGH in this case (Continued)
19p13.11 19143788-19306349 0.16 9
20q11.1-q13.32 28125216-56612507 28.5 408
20q13.32-qter 57343940-62387649 5.0 110
21q22.13-q22.3 38293990-45156291 6.9 120
22q12.3 31618959-34862722 3.3 23
22q13.1 36256330-37868873 1.6 55
22q13.1-qter 37975088-49581355 11.6 207
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qter, 9p24.1, 9q34.11, 9q34.3, 10pter-q22.1, 11pter-p15.4,
14q12-qter, 15q, 16pter-p13.3, 17pter-p12, 19p13.3-
13.11, 20q13.32-qter, 22q12.3, and 22q13.1-qter. The
tumor had gains on 1pter-p36.33, 2pter-p25.3, 2q14.1, as
well as several regions on the short arm of chromosome
4, 4q31.1, 5pter-p15.31, 5q34, 5q35.2-qter, 6q22.33,
19p13.11, 20q11.1-q13.32, 21q22.13-q22.3, and 22q13.1.
To confirm a selection of the tumor-related regions
detected by the aCGH assay, FISH was performed using
multiple corresponding DNA probes. A total of 200 cells
were analyzed for each probe used. Approximately 80%






Figure 2 FISH analysis using selective probes confirmed the aCGH res
signals of LSI D5S21 (green), indicating a loss of the EGR1 gene. (B) One sig
(C) One signal of the LSI IGH (green) indicates a loss of the IGH gene, and
One signal of the LSI TP53 indicates a loss of the TP53 gene.including EGR1 (5q31.2), MYC (8q24.21), IGH (14q32.2)
and TP53 (17p13.1) as well as a gain of FGFR3 (4p16.3)
(Figure 2A-D). A point mutation (C>T) in TP53 gene
exon 7 at nucleotide 13379 (g.13379 C>T) resulting in
the substitution of an arginine for a methionine at codon
248 (R248W) was identified in this case (Figure 3).
Discussion
To compare our aCGH findings with previous conven-
tional CGH data generated by Sowery et al. [8], we sum-
marized our current case and their six cases of UESL into
a chromosome idiogram (Figure 4). Our investigation of




ults. (A) It showed only one signal of the LSI EGR1 (red) and two
nal of the LSI c-MYC (yellow) demonstrates a loss of the MYC gene.




Figure 3 A point mutation (C>T) in TP53 gene at nucleotide 13379 (g.13379 C>T) resulting in the substitution of an arginine for a
methionine at codon 248 (R248W) was detected in the tumor tissue.
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http://www.molecularcytogenetics.org/content/5/1/26genomic imbalances involving gains of regions on
chromosome 2 (2pter-p25.3 and 2q14.1), 19p13.11,
21q22.13-q22.3, and 22q13.1, as well as deletions of
1p13.1, alternating deletions on 5q (5q21.2-5q33.3),
8q24.12-qter, 9q (9q34.11 and 9q34.3), 15q11.2-qter,
16pter-p13.3, 17pter-p12, 19p13.3-p13.11, 20q13.32-qter,
and 22q (22q12.3 and 22q13.1-qter). In addition to these
regions mentioned above, twelve non-copy number
variants, either segmental losses or gains less than 1 Mb
were also identified on different chromosomes. Eight of
these twelve smaller segments distributed on chromosome


























c : current case
— : < 1.0Mb
Figure 4 Idiograms of the aCGH results from our case along with six
et al. Our current case is labeled as “c” and gains of our case are presented
red vertical patterned lines. “—” represent segments of losses or gains sma
green vertical lines to the right of the chromosome idiograms; losses are dimbalanced segments or embedded in the middle of the
alternating multi-deletion regions. These smaller segmen-
tal changes are more likely due to the chromosomal in-
stability. Four out of twelve smaller segments, located on
chromosome 6 and 9, were isolated independently from
other genomic imbalanced regions, and at least one of
these regions on 9q contains tumor-related genes (NAIF1
and CIZ1). We also identified imbalanced regions that
overlapped with regions reported by Sowery et al., i.e., 3p
(loss), 4p (gain), 11p (loss), 14q (loss), and 20q (gain).
Our case showed more loss, approximately 645.3 Mb












cases using conventional CGH previously reported by Sowery
by green vertical patterned lines. Losses of our case are presented by
ller than 1 Mb. For Sowery et al.’s study, gains are demonstrated by
emonstrated by red vertical lines to the left.
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patterns of loss vs. gain were found, i.e., more gain than
loss was shown using visual observation of the idiogram
(summarized in Figure 4). A few imbalanced regions in
our case are worth emphasizing. Alternating, multiple
segmental deletions within the 5q21.2–5q33.3 region
were detected (Figure 5). The sizes of the alternating
deleted segments ranged from 69 kb to 7.6 Mb. It is im-
possible to detect these deletion patterns with routine
cytogenetic techniques or conventional CGH. The
results from the aCGH illustrated that the chromosomal
instability in tumors is more complicated than a simple
deletion, duplication or translocation. This phenomenon
of alternating multiple segmental deletions has been
reported in other types of solid tumors [13-15]. The
same is true for the deletions on chromosome 8q
(8q24.12-qter) and 17p (17pter-p12) detected in our
study as opposed to the duplications reported by Sowery
et al. We proceeded with a mutation assay of the TP53
gene located on chromosome 17p. A missense mutation
R248W of the remaining allele was found. To our know-
ledge, this is the fourth UESL case reported to carry the
TP53 gene mutation [10,11]. This particular mutation,
as a somatic or germline change, has been reported in a
variety of solid tumors [16]. Interestingly, all these muta-
tions, identified in cases with UESL, namely, K120M
[11], V216M [11], S245G [10], and R248W (our case)
are located in the sequence-specific DNA binding do-
main (amino acid residues 102–292 out of the 393 of
the p53 protein), where the hot spots of mutations are
located [17]. The major consequence of these mutations
in this domain is loss of sequence-specific DNA binding
to the canonical p53-binding site and loss of the ability
to induce cell cycle arrest or apoptosis. It has beenFigure 5 Array-CGH result of alternating multiple segmental deletion
SegMNT. Red arrows indicate the loss of chromosome material.reported that ellipticine may restore the DNA binding
domain and transcription function in transfected p53
mutants cells with different mutations in this sequence-
specific DNA binding domain [18]. This could lead to a
potential targeted therapy of UESL via restoring the bio-
logical activity of p53.
Three out of six patients in Sowery et al.’s study
showed a loss of the whole long arm of chromosome 14.
In our case, a partial deletion of the long arm (14q12-
qter) was detected. This could be a pure deletion of the
long arm of chromosome 14 at the breakpoint 14q12, or
it could be due to an unbalanced translocation with an-
other partner chromosome. Although loss of chromo-
some 14 has been reported in rhabdomyosarcoma and
neuroblastoma and associated with poor outcomes in
clear-cell renal cell carcinoma [19-21], it is unclear
whether the loss of chromosome 14 plays an important
role in UESL initiation or progression. In Sowery et al.’s
assay, three out of six cases presented a gain of 5p with
an overlapped region of 5pter-p13.3. Our case also had a
gain of the short arm of chromosome 5, but the size was
reasonably smaller, of only 6.2 Mb. In the literature, a
gain of 5p has been found in osteosarcoma and malig-
nant fibrous histiocytoma [22], and studies combining
aCGH and gene expression assays suggest that 5pter-
p15.3 harbors several candidate oncogenes including
TRIP13, TERT, NDUFS6, and ADAMT16 [13,14]. A gain
of 4p with an overlapped region of 4pter-p15.2 was
detected by our study and Sowery’s group. FISH using
the LSI LGH/FGFR3 probe revealed an amplification of
the FGFR3 gene in this region (Figure 2C). FGFR3
amplification and/or overexpression was reported in
rhabdomyosarcoma and bladder cancer [23,24]. These
recurrent findings may be critical to the development ofs on chromosome 5q of the current case using NimbleGen
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Losses of segments on 3p and 11p were shared by both
studies, but Sowery’s group also detected gains in these
regions. This phenomenon could be due to the second-
ary chromosomal changes.
In the literature, multiple karyotypic analyses reported
that UESL frequently harbors t(11;19)(q11;q13.3/13.4)
[6,7,25]. However, this was not noted either in our case or
in Sowery et al.’s study. UESL shares similar clinical and
histological features and a genetic profile with mesenchy-
mal hamartoma of the liver (MHL). Over the past few
years, three cases of UESL have been reported to develop
within MHL, displaying similar genetic rearrangements
involving either an add(19)(q13.4) or t(11;19)(q11;q13.3-
13.4), nearly identical to the genetic rearrangements
observed in previous solitary cases of MHL [6,7,25].
Rajaram et al. have postulated that the t(11;19) transloca-
tion is likely related to the development of solitary cases of
MHL, but for progression of MHL to UESL, additional
genetic alterations at other loci are required [9].
Based on our high-resolution aCGH data, numerous
genes were located in the imbalanced regions, and some
of them were tumor-related genes. In addition to the
genes mentioned above, several notable genes that are
worth further investigation are listed in Table 1.
In conclusion, although numerous chromosomal abnor-
malities and tumor-related genes were identified in this
case, the tumorigenic mechanism of UESL is still unclear.
Further investigations are required; however, the clinical
diagnosis of UESL is difficult because there are limitations
associated with determining morphological classifications.
The effort to find genetic markers to subclassify UESL is
important, and genomic profiles will assist in current clin-
ical practices. In addition, we also emphasized the inacti-
vation of TP53 gene through the loss of heterozygosity
and a pathogenic mutation of the remaining allele. Restor-
ation of TP53 gene function could be of interest for thera-
peutic strategies of UESL. Our findings shed new light on
the clinical diagnosis and add strong evidence of a poten-
tial targeted treatment.
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